Form 4: BeOne Medicines CEO John Oyler Sells Over 27,000 ADSs Through Pre-Arranged Trading Plan

BeOne Medicines Ltd. CEO and Director John Oyler executed the sale of 27,802 American Depositary Shares (ADSs) on July 9, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• John Oyler, the Chief Executive Officer and a Director of BeOne Medicines Ltd. (ONC), reported transactions involving the sale of American Depositary Shares (ADSs).
• The sales occurred on July 9, 2025, and were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Oyler on March 12, 2025.
• A total of 27,802 American Depositary Shares were sold across multiple transactions.
• The sales were executed at weighted average prices ranging from $252.2277 to $254.8337 per ADS.
• Specifically, 6,703 ADSs were sold at $252.2277, 9,292 ADSs at $253.1828, 10,254 ADSs at $254.1035, and 1,553 ADSs at $254.8337.
• Each American Depositary Share represents 13 Ordinary Shares.
• Following these transactions, Mr. Oyler's direct beneficial ownership of American Depositary Shares is 0.
• Mr. Oyler continues to directly own 7,812,333 Ordinary Shares.
• Indirect beneficial ownership includes 481,533 Ordinary Shares held by the P&O Trust, 7,722,480 Ordinary Shares in a grantor retained annuity trust, 28,204,115 Ordinary Shares held by Oyler Investment LLC, 9,545,000 Ordinary Shares in a Roth IRA PENSCO trust account, and 102,188 Ordinary Shares held by The John Oyler Legacy Trust, for which Mr. Oyler disclaims beneficial ownership in most cases.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the fact that it was executed under a pre-arranged Rule 10b5-1 plan mitigates concerns that it is based on new, negative material information. It suggests a planned liquidity event or portfolio diversification.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, which was adopted on March 12, 2025, indicating a pre-scheduled transaction rather than a reaction to recent non-public information.

Negatives

• A significant sale of shares by a Chief Executive Officer and Director, totaling 27,802 American Depositary Shares, represents a reduction in direct insider ownership.

Risks

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, potentially leading to downward pressure on the stock price due to concerns about management's confidence or liquidity needs.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2025.

Industry Context

This Form 4 filing is specific to insider transactions at BeOne Medicines Ltd. and does not provide broader industry context or trends.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale by a key executive could be interpreted as a signal regarding the executive's confidence in the company, although the 10b5-1 plan mitigates this. It also represents a reduction in direct insider alignment with shareholder interests through equity ownership.

Key Dates

Recommendation

Keywords

BeOne Medicines, ONC, John Oyler, SEC Form 4, Insider Trading, Stock Sale, American Depositary Shares, ADS, Rule 10b5-1 Plan, CEO, Director, Beneficial Ownership